Search - tctmd.com

Displaying 421 - 440 of 771

Sort: Relevancy | Date

News Daily News

ADAPT-DES 亚组研究：实践变化可能会进一步降低已处于低水平的支架血栓发生率

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Caitlin E. Cox

October 06, 2015

News Daily News

Transradial PCI May Attenuate Bivalirudin Benefits

Todd Neale

October 05, 2015

News Daily News

PCI Transradial podría atenuar los beneficios de la bivalirudina

Todd Neale

October 05, 2015

News Daily News

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Yael L. Maxwell

September 18, 2015

News Daily News

RECLOSE-3: Cambiar a Clopidogrel a No Respondedores al Prasugrel Reduce la Mortalidad Post-PCI

Yael L. Maxwell

September 18, 2015

News Daily News

RECLOSE-3：对氯吡格雷无反应者改用普拉格雷可降低PCI术后死亡率

Yael L. Maxwell

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

DAPT Analysis Eases Concerns Over Slightly Higher Death Rate Seen With Extended Thienopyridine Use

Caitlin E. Cox

September 01, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2015

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

Caitlin E. Cox

August 31, 2015

News Daily News

La Localización de la EAC Puede Influir en la Necesidad de Recibir Tratamiento Antiplaquetario Prolongado Post-PCI

Caitlin E. Cox

August 24, 2015

News Daily News

CAD Location May Influence Need for Prolonged DAPT Post-PCI

Caitlin E. Cox

August 24, 2015

News Daily News

CAD的位置可影响PCI术后对延长DAPT的需求

Caitlin E. Cox

August 24, 2015

Advertisement

ADAPT-DES 亚组研究：实践变化可能会进一步降低已处于低水平的支架血栓发生率

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Transradial PCI May Attenuate Bivalirudin Benefits

PCI Transradial podría atenuar los beneficios de la bivalirudina

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

RECLOSE-3: Cambiar a Clopidogrel a No Respondedores al Prasugrel Reduce la Mortalidad Post-PCI

RECLOSE-3：对氯吡格雷无反应者改用普拉格雷可降低PCI术后死亡率

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

DAPT Analysis Eases Concerns Over Slightly Higher Death Rate Seen With Extended Thienopyridine Use

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

La Localización de la EAC Puede Influir en la Necesidad de Recibir Tratamiento Antiplaquetario Prolongado Post-PCI

CAD Location May Influence Need for Prolonged DAPT Post-PCI

CAD的位置可影响PCI术后对延长DAPT的需求

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content